Tilray Brands (TLRY) Liabilities and Shareholders Equity (2017 - 2026)
Tilray Brands (TLRY) reported Liabilities and Shareholders Equity of $2.1 billion for Q1 2026, down 1.14% quarter-over-quarter from $2.1 billion in Q4 2025.
Tilray Brands (TLRY) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Tilray Brands has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $2.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $2.1 billion; the trailing twelve-month figure through Feb 2026 stood at $8.3 billion (down 34.28% YoY), and the FY2025 full-year result was $2.1 billion, down 50.86% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $2.1 billion, down from $2.1 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $5.8 billion in Q1 2022, with the low at $2.1 billion in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $4.1 billion across 5 years, with a median of $4.3 billion in 2023.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity declined 1.99% — and 2025, when it slumped 51.13%.
- Tilray Brands' Liabilities and Shareholders Equity stood at $5.5 billion in 2022, then retreated by 20.89% to $4.3 billion in 2023, then dropped by 3.21% to $4.2 billion in 2024, then plunged by 49.94% to $2.1 billion in 2025, then decreased by 1.14% to $2.1 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $2.1 billion (Q1 2026), $2.1 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.35 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 2.27 Bn |
| 10 | Tilray Brands | - | - | 54.95 Mn | 2.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 2.07 Bn |
| Nov 30, 2025 | 2.10 Bn |
| Aug 31, 2025 | 2.08 Bn |
| May 31, 2025 | 2.07 Bn |
| Nov 30, 2024 | 4.19 Bn |
| Aug 31, 2024 | 4.26 Bn |
| May 31, 2024 | 4.22 Bn |
| Feb 29, 2024 | 4.21 Bn |
| Nov 30, 2023 | 4.33 Bn |
| Aug 31, 2023 | 4.40 Bn |
| May 31, 2023 | 4.31 Bn |
| Feb 28, 2023 | 4.38 Bn |
| Nov 30, 2022 | 5.47 Bn |
| Aug 31, 2022 | 5.59 Bn |
| May 31, 2022 | 5.45 Bn |
| Feb 28, 2022 | 5.82 Bn |
| Nov 30, 2021 | 5.76 Bn |
| Aug 31, 2021 | 5.99 Bn |
| May 31, 2021 | 6.03 Bn |
| May 31, 2020 | 1.74 Bn |